Open Access
Hypotensive therapу of secondary glaucoma in patients with endocrine ophthalmopathy
Author(s) -
О. П. Садовская
Publication year - 2021
Publication title -
problemy zdorovʹâ i èkologii
Language(s) - English
Resource type - Journals
eISSN - 2708-6011
pISSN - 2220-0967
DOI - 10.51523/2708-6011.2021-18-2-7
Subject(s) - medicine , intraocular pressure , glaucoma , combination therapy , ophthalmology , endocrine system , prostaglandin analogue , prostaglandin , hormone
Objective: to evaluate the efciency of monotherapy and xed combination therapy of secondary glaucoma (SG) in patients with endocrine ophthalmopathy (EOP). Materials and methods. We examined 145 patients (290 eyes and orbits) with different forms and activity of EOP. Among them, 30 patients (58 eyes and orbits) were diagnosed with ″SG detected for the rst time and associated with EOP″ (20 % of the cases). The patients with SG received beta-adrenoblockers (BA) or prostaglandin analogues (PGA) as initial monotherapy. Two weeks later, in the absence of intraocular pressure (IOP) compensation, xed combinations of beta-blocker/carbonic or anhydrase inhibitor (BB/CAI) or beta-blocker/prostaglandin analogue (BB/ PGA) were prescribed. Results. The PGA monotherapy reduced the IOP level by 29 % compared to the baseline level in 33 % of the cases in increased ophthalmic tonus within Me 27 [26;28] mm Hg. (Wilcoxon test, p = 0.005). In IOP levels over 29 [28;31] mmHg, BB/PGA xed combination therapy reduced IOP by 33 % from the baseline level. Conclusion. SG monotherapy in patients with EOP is effective in increased IOP within Me 27 [26;28] mmHg. In initial IOP levels higher than 29 [28;31] mmHg, it is expedient to prescribe BB/PGA xed combination therapy as initial therapy.